Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP186403.RALuE7UnyAI2ui4aLnDt93P4mWw5cwQApMQ-TSa0BGcpA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP186403.RALuE7UnyAI2ui4aLnDt93P4mWw5cwQApMQ-TSa0BGcpA130_assertion type Assertion NP186403.RALuE7UnyAI2ui4aLnDt93P4mWw5cwQApMQ-TSa0BGcpA130_head.
- NP186403.RALuE7UnyAI2ui4aLnDt93P4mWw5cwQApMQ-TSa0BGcpA130_assertion description "[In this pilot investigation, we found an increased prevalence of the CYP2C8*4 mutation in the Type 2 diabetic patient group. This may result in a modification of drug degradation and drug efficacy in these patients and may have an influence, e.g. on the c]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP186403.RALuE7UnyAI2ui4aLnDt93P4mWw5cwQApMQ-TSa0BGcpA130_provenance.
- NP186403.RALuE7UnyAI2ui4aLnDt93P4mWw5cwQApMQ-TSa0BGcpA130_assertion evidence source_evidence_literature NP186403.RALuE7UnyAI2ui4aLnDt93P4mWw5cwQApMQ-TSa0BGcpA130_provenance.
- NP186403.RALuE7UnyAI2ui4aLnDt93P4mWw5cwQApMQ-TSa0BGcpA130_assertion SIO_000772 20857895 NP186403.RALuE7UnyAI2ui4aLnDt93P4mWw5cwQApMQ-TSa0BGcpA130_provenance.
- NP186403.RALuE7UnyAI2ui4aLnDt93P4mWw5cwQApMQ-TSa0BGcpA130_assertion wasDerivedFrom gad-20150221 NP186403.RALuE7UnyAI2ui4aLnDt93P4mWw5cwQApMQ-TSa0BGcpA130_provenance.
- NP186403.RALuE7UnyAI2ui4aLnDt93P4mWw5cwQApMQ-TSa0BGcpA130_assertion wasGeneratedBy ECO_0000203 NP186403.RALuE7UnyAI2ui4aLnDt93P4mWw5cwQApMQ-TSa0BGcpA130_provenance.